112 related articles for article (PubMed ID: 10723506)
21. Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors.
Balzarini J
Pharmacol Ther; 2000; 87(2-3):175-87. PubMed ID: 11007999
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
Giacca M; Borella S; Calderazzo F; Bianchi LC; D'Agaro P; Rampazzo C; Bianchi V; Reichard P
AIDS Res Hum Retroviruses; 1996 May; 12(8):677-82. PubMed ID: 8744578
[TBL] [Abstract][Full Text] [Related]
23. Role of immune modulation in primary HIV infection.
Lori F; Lisziewicz J
J Biol Regul Homeost Agents; 2000; 14(1):45-8. PubMed ID: 10763893
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
25. Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta-chemokines: a strategy to inhibit R5 HIV-1.
Heredia A; Davis C; Amoroso A; Dominique JK; Le N; Klingebiel E; Reardon E; Zella D; Redfield RR
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4179-84. PubMed ID: 12644703
[TBL] [Abstract][Full Text] [Related]
26. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Zala C; Salomón H; Cahn P
Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
[TBL] [Abstract][Full Text] [Related]
27. 5-Amino-4-imidazolecarboxamide riboside potentiates the metabolism and anti-human immunodeficiency virus activity of 2',3'-dideoxyinosine.
Gong YF; Srinivas RV; Fridland A
Mol Pharmacol; 1993 Jul; 44(1):30-6. PubMed ID: 8341276
[TBL] [Abstract][Full Text] [Related]
28. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
Lori F; Malykh A; Cara A; Sun D; Weinstein JN; Lisziewicz J; Gallo RC
Science; 1994 Nov; 266(5186):801-5. PubMed ID: 7973634
[TBL] [Abstract][Full Text] [Related]
29. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.
Gao HQ; Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Mol Biol; 2000 Jul; 300(2):403-18. PubMed ID: 10873473
[TBL] [Abstract][Full Text] [Related]
30. 2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis.
Ahluwalia GS; Gao WY; Mitsuya H; Johns DG
Mol Pharmacol; 1996 Jul; 50(1):160-5. PubMed ID: 8700108
[TBL] [Abstract][Full Text] [Related]
31. Use of hydroxyurea in heavily pretreated patients with HIV infection.
Hermans P; De Wit S; Sommereijns B; O'Doherty E; Clumeck N
Antivir Ther; 1999; 4 Suppl 3():19-22. PubMed ID: 16021867
[TBL] [Abstract][Full Text] [Related]
32. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
[TBL] [Abstract][Full Text] [Related]
33. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea.
Schläpfer E; Fischer M; Ott P; Speck RF
AIDS; 2003 Jul; 17(11):1613-20. PubMed ID: 12853743
[TBL] [Abstract][Full Text] [Related]
34. The nucleoside analogs 4'C-methyl thymidine and 4'C-ethyl thymidine block DNA synthesis by wild-type HIV-1 RT and excision proficient NRTI resistant RT variants.
Boyer PL; Julias JG; Ambrose Z; Siddiqui MA; Marquez VE; Hughes SH
J Mol Biol; 2007 Aug; 371(4):873-82. PubMed ID: 17597154
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
Aquaro S; Svicher V; Schols D; Pollicita M; Antinori A; Balzarini J; Perno CF
J Leukoc Biol; 2006 Nov; 80(5):1103-10. PubMed ID: 16931601
[TBL] [Abstract][Full Text] [Related]
36. Hydroxyurea, a potential new anti-HIV agent.
Torres G
GMHC Treat Issues; 1995 Jan; 9(1):7-9. PubMed ID: 11367381
[TBL] [Abstract][Full Text] [Related]
37. Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.
Meng Q; Su T; O'Neill JP; Walker VE
Environ Mol Mutagen; 2002; 39(4):282-95. PubMed ID: 12112380
[TBL] [Abstract][Full Text] [Related]
38. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
[TBL] [Abstract][Full Text] [Related]
39. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
Lori F; Malykh AG; Foli A; Maserati R; De Antoni A; Minoli L; Padrini D; Degli Antoni A; Barchi E; Jessen H; Wainberg MA; Gallo RC; Lisziewicz J
AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1403-9. PubMed ID: 9359660
[TBL] [Abstract][Full Text] [Related]
40. Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription.
Roy B; Chambert S; Lepoivre M; Aubertin AM; Balzarini J; Décout JL
J Med Chem; 2003 Jun; 46(13):2565-8. PubMed ID: 12801219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
